Aim: Advanced glycation end products (AGEs) and/or their receptors (RAGE) are significantly positively correlated with adiposity, inflammation, dyslipidemia, and insulin resistance in adults. However, the relationships between AGEs, RAGE, and adiposity-related comorbidites in children have not been well studied. Methods: In a cross-sectional study of 88 children (age 11-15 years) from the New York area enrolled in the Reduce Obesity and Diabetes (ROAD) study, we examined the correlation of the AGE Nε-(carboxymethyl)lysine (CML), soluble RAGE (sRAGE), and endogenous secretory RAGE (esRAGE) with adiposity, inflammatory markers [interleukin-6 (IL-6), C-reactive protein, tumor necrosis factor-α], adiponectin, lipids, insulin sensitivity, and insulin secretory capacity. Results: Pediatric CML levels were ∼20% below average adult levels. CML was significantly (p < 0.05) positively correlated with age and insulin sensitivity and negatively with adiposity, dyslipidemia and IL-6. sRAGE correlated positively with esRAGE and negatively with adiposity and IL-6. Both sRAGE and esRAGE correlated negatively with insulin secretory capacity. Conclusion: Our findings suggest that unlike adults, CML is negatively associated with adiposity and adiposity-related comorbidity risk in children. As in adults, sRAGE and esRAGE were, to varying degrees, negatively correlated with body fatness and risk factors for adiposity-related comorbidities.

Keywords:
Nε-(carboxymethyl)lysine, Soluble RAGE, Endogenous secretory RAGE, Pediatric obesity, Insulin resistance
1.
Rosenbaum M: Epidemiology of pediatric obesity. Pediatr Ann 2007;36:89-95.
2.
Unger R, Kreeger L, Christoffel KK: Childhood obesity. Medical and familial correlates and age of onset. Clin Pediatr (Phila) 1990;29:368.
3.
Matsuzawa Y, Funahashi T, Nakamura T: The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb 2011;18:629-639.
4.
Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9.
5.
Goldin A, Beckman JA, Schmidt AM, Creager MA: Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006;114:597-605.
6.
Kwon, J-H, Kim YH, Kwon JY, Park YW: Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia. J Perinat Med 2011;30:507-513.
7.
D'Adama Giannini C, Chiavaroli V, de Giorgis T, Verrotti A, Chiarelli F, Mohn A: What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children. Antioxid Redox Signal 2011;14:1167-1172.
8.
Gugliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M, Egawa K, Horikawa C, Kitagawa Y, Kiso Y, Kimura S, Sakane N: Short term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009;54:197-201.
9.
Schmidt A, Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-955.
10.
Sebeková K, Somoza V, Jarcusková M, Heidland A, Podracká L: Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 2009;4:112-118.
11.
Chiavaroli V, D'Adamo E, Giannini C, de Giorgis T, De Marco S, Chiarelli F, Mohn A: Serum levels of receptors for advanced glycation end products in normal-weight and obese children born small and large for gestational age. Diabetes Care 2012;35:1361-1363.
12.
Peppa M, Raptis S: Advanced glycation end products and cardiovascular disease. Curr Diab Rev 2008;4:92-100.
13.
Rosenbaum M, Accacha SD, Altshuler LA, Carey DE, Fennoy I, Lowell BC, Rapaport R, Speiser PW, Shelov SP: The Reduce Obesity and Diabetes (ROAD) project: design and methodological considerations. Child Obes 2011;7:223-234.
14.
American Physiological Society, World Medical Association General Assembly: Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol 2002;283:R281-R283.
15.
Rosenbaum M, Nonas C, Horlick M, Fennoy I, Vargas I, Schachner H, Kringas P, Stanton K, Weil R, Camino Diabetes Prevention Group: Beta-cell function and insulin sensitivity in early adolescence: association with body fatness and family history of type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89:5469-5476.
16.
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
17.
Zethelius B, Byberg L, Hales CN, Lithell H, Berne C: Proinsulin and acute insulin response independently predict type 2 diabetes mellitus in men - report from 27 years of follow-up study. Diabetologia 2003;46:20-26.
18.
Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19.
19.
Flegal K, Cole T: Construction of LMS parameters for the centers for disease control and prevention 2,000 growth charts. National Health Statistics Reports. 2013, vol 63.
20.
Ford ES, Mokdad AH, Ajani UA: Trends in risk factors for cardiovascular disease among children and adolescents in the United States. Pediatrics 2004;114:1534-1544.
21.
Hickman TB, Briefel RR, Carroll MD, Rifkind BM, Cleeman JI, Maurer KR, Johnson CL: Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med 1998;27:879-890.
22.
Perneger TV: What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-1238.
23.
Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-46.
24.
Thomas DC, Siemiatycki J, Dewar R, Robins J, Goldberg M, Armstrong BG: The problem of multiple inference in studies designed to generate hypotheses. Am J Epidemiol 1985;122:1080-1095.
25.
Yang SJ, Kim S, Hwang SY, Kim TN, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM: Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. Atherosclerosis 2012;220:402-406.
26.
Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL: Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2009;19:129-134.
27.
Hofmann SM, Dong HJ, Li Z, Cai W, Altomonte J, Thung SN, Zeng F, Fisher EA, Vlassara H: Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002;51:2082-2089.
28.
Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H: Insulin resistance and type 2 diabetes in high fat fed mice are linked to high glycotoxin intake. Diabetes 2005;54:2314-2319.
29.
Tahara R, Yamagishi SI, Matsui T: Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012;30:42-48.
30.
Semba RD, Arab L, Sun K, Nicklett EJ, Ferrucci L: Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr 2011;141:1726-1730.
31.
Kuniyasu A, Ohgarni N, Hayashi S, Miyazaki A, Horiuchi S, Nakayama H: CD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3-Ll and human subcutaneous adipocytes. FEBS Lett 2003;537:85-90.
32.
Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li YM, Bucala R, Vlassara H: Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 1997;3:617-627.
33.
Galler A, Müller G, Schinzel R, Kratzsch J, Kiess W, Münch G: Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and N-(carboxymethyl) lysine ELISA. Diabetes Care 2003;26:2609-2615.
34.
Pertyńska-Marczewska M, Kiriakidis S, Wait R, Beech J, Feldmann M, Paleolog EM: Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages. Cytokine 2004;28:35-47.
35.
Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW: The myeloperoxidase system of human phagocytes generates N-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999;104:103-113.
36.
Vlassara H: Advanced glycation in health and disease: role of the modern environment. Ann NY Acad Sci 2005;1043:452-460.
37.
Sebeková K, Podracká L, Heidland A, Schinzel R: Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation - are they inter-related? Clin Nephrol 2001;56:S21-S26.
38.
Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H: Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007;62:427-433.
39.
Cai W, He JC, Zhu L, Lu C, Vlassara H: Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006;103:13801-13806.
40.
Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, Zhu L, Striker GE, Vlassara H: Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011;34:1610-1616.
41.
Vlassara H, Uribarri J, Cai W, Striker G: Advanced glycation end product homeostasis: exogenous oxidants and innate defenses. Ann N Y Acad Sci 2008;1126:46-52.
42.
Hudson BI, Moon YP, Kalea AZ, Khatri M, Marquez C, Schmidt AM, Paik MC, Yoshita M, Sacco RL, DeCarli C, Wright CB, Elkind MS: Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 2011;216:192-198.
43.
Nakamura K, Adachi H, Matsui T, Kurita Y, Takeuchi M, Yamagishi S: Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients. Metabolism 2009;58:421-425.
44.
Koga M, Otsuki M, Matsumoto S, Saito H, Mukai M, Kasayama S: Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin Chem Acta 2007;378:48-52.
45.
Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: N-(carboxymethyl) lysine protein adduct is a major immunological epitote in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996;35:8075-8083.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.